PROVEN EFFICACY

According to a head-to-head randomized controlled trial, FLUBLOK QUADRIVALENT was proven to provide better protection versus a standard-dose quadrivalent inactivated influenza vaccine1,2:

Primary Endpoint
30
(95% CI: 10-47)
%
Better Protection
from Influenza
due to any PCRb-confirmed strain1,2
Primary Endpoint Definition: The primary endpoint of the study was PCR-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.1,2

b PCR = Polymerase chain reaction.

Secondary Endpoint
43
(95% CI: 21-59)
%
Better Protection
from Influenza
due to any culture-confirmed strain1,2
Secondary Endpoint Definition: The secondary endpoint of the study was culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.1,2

INDICATION FOR FLUBLOK QUADRIVALENT VACCINE

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.

SIMILAR SAFETY PROFILE in adults 50+ (N=4,312) compared with a standard-dose quadrivalent inactivated influenza vaccine (N=4,327)1


Fluzone Quadrivalent Vaccine Injection-Site and System Reactions Fluzone Quadrivalent Vaccine Injection-Site and System Reactions

Two separate studies in adults showed that rates of local and systemic adverse reactions were similar among Flublok Quadrivalent and Fluarix® Quadrivalent recipients1

AN INFLUENZA VACCINE WITH A UNIQUE COMPOSITION

  • 3X more hemagglutinin antigen versus a standard-dose quadrivalent inactivated influenza vaccine3
  • Similar safety profile compared to a standard-dose inactivated influenza vaccine2
  • Made with RECOMBINANT DNA TECHNOLOGY2:
    • Eliminates the need to grow influenza virus during manufacturing, which ensures hemagglutinin antigen cannot adapt or mutate
    • Avoids changes in hemagglutinin antigen structure that can lead to reduced vaccine effectiveness

Recombinant DNA Technology Avoids Antigenic Adaptations and Mutations2

Fluzone Quadrivalent Vaccine Injection-Site and System Reactions

b WHO = World Health Organization.